INCIDENCE OF ENDOPHTHALMITIS RELATED TO INTRAVITREAL INJECTION OF BEVACIZUMAB AND RANIBIZUMAB

2008215 citationsJournal Article

Authors

David R. Fintak · Retina Institute

Gaurav K. Shah · Retina Institute

Kevin J. Blinder · Retina Institute

Carl D. Regillo · Wills Eye Hospital

John S. Pollack · Illinois Retina Associates

Jeffrey S. Heier · Ophthalmic Consultants of Boston

Hussein Hollands ·

Abstract

The rate of endophthalmitis associated with intravitreal bevacizumab and ranibizumab is low, with an incidence of approximately 1 in 4,500 injections.

Topics & Keywords

Ocular Infections and Treatments Retinal Diseases and Treatments Ocular Diseases and Behçet’s Syndrome

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Retina

Volume 28, Issue 10, pp. 1395-1399

DOI: 10.1097/iae.0b013e3181884fd2

Field-Weighted Citation Impact: 18.33

Command Palette